Join to View Full Profile
9430 Key West AveSte 113Rockville, MD 20850
Dr. Zheng is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
NYU Grossman School of MedicineResidency, Pathology-Anatomic and Clinical, 1994 - 1998
Peking Union Medical CollegeClass of 1987
Certifications & Licensure
MD State Medical License 2014 - 2025
DC State Medical License 2015 - 2022
MI State Medical License 2006 - 2022
VA State Medical License 2014 - 2020
OH State Medical License 1998 - 2007
NY State Medical License 1997 - 1999
American Board of Pathology Clinical Pathology
Clinical Trials
- Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Start of enrollment: 2020 Sep 16
Publications & Presentations
PubMed
- pH-dependent dissociation from CTLA-4 in early endosomes improves both safety and antitumor activity of anti-CTLA-4 antibodies.Meiyu Zhang, Jinmei Li, Kepeng Yan, Haoyue Zhou, Song Mei
Proceedings of the National Academy of Sciences of the United States of America. 2025-02-25 - IL-27 Gene Therapy Ameliorates IPEX Syndrome Caused by Germline Mutation of Foxp3 Gene: A Major Role for Induction of IL-10.Jin-Qing Liu, Ali Jabbari, Cho-Hao Lin, Venu Akkanapally, Wendy L Frankel
Journal of Immunology. 2024-09-01 - 3 citationsA phase 2 trial of CD24Fc for prevention of graft-versus-host disease.John Magenau, Samantha Jaglowski, Joseph Uberti, Sherif S Farag, Mary Mansour Riwes
Blood. 2024-01-04
Journal Articles
- CD24 and Fc Fusion Protein Protects SIVmac239-Infected Chinese Rhesus Macaque Against Progression to AIDSPan Zheng, MD, ScienceDirect
Press Mentions
UPDATE - OncoC4 Announces First Patient Dosed in PRESERVE-004, a Phase 2 Clinical Trial of ONC-392 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Platinum-Resistant Ovarian CancerDecember 30th, 2022- OncoC4 Announces First Patient Dosed in PRESERVE-004, a Phase 2 Clinical Trial of ONC-392 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Platinum-Resistant Ovarian CancerDecember 30th, 2022
- OncoC4 to Present Positive Data from Ongoing Phase 1/2 PRESERVE-001 Trial of ONC-392 in Combination with Pembrolizumab at SITC 2022November 7th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
